Presentation is loading. Please wait.

Presentation is loading. Please wait.

Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network.

Similar presentations


Presentation on theme: "Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network."— Presentation transcript:

1 Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry  Raja Dhar, MD, Sheetu Singh, MD, Deepak Talwar, MD, Prof Murali Mohan, MD, Surya Kant Tripathi, MD, Rajesh Swarnakar, DNB, Sonali Trivedi, DNB, Prof Srinivas Rajagopala, MD, George D'Souza, MD, Arjun Padmanabhan, MD, Archana Baburao, DNB, Padukudru Anand Mahesh, MD, Prof Babaji Ghewade, MD, Prof Girija Nair, MD, Aditya Jindal, DM, Prof Gayathri Devi H Jayadevappa, MD, Honney Sawhney, MD, Kripesh Ranjan Sarmah, MD, Kaushik Saha, MD, Suresh Anantharaj, DNB, Arjun Khanna, DM, Samir Gami, MD, Arti Shah, DNB, Arpan Shah, DNB, Naveen Dutt, MD, Himanshu Garg, MD, Sunil Vyas, DNB, Kummannoor Venugopal, MD, Prof Rajendra Prasad, MD, Prof Naveed M Aleemuddin, MD, Saurabh Karmakar, MD, Virendra Singh, MD, Surinder Kumar Jindal, MD, Shubham Sharma, MBBS, Deepak Prajapat, MD, Sagar Chandrashekaria, DNB, Melissa J McDonnell, MSc, Aditi Mishra, MBBS, Robert Rutherford, MD, Prof Ramanathan Palaniappan Ramanathan, MD, Pieter C Goeminne, PhD, Preethi Vasudev, DTCD, Katerina Dimakou, PhD, Megan L Crichton, MFM, Biiligere Siddaiah Jayaraj, DM, Rahul Kungwani, MD, Akanksha Das, MD, Mehneet Sawhney, MBBS, Eva Polverino, PhD, Prof Antoni Torres, MD, Nayan Sri Gulecha, MBBS, Michal Shteinberg, PhD, Prof Anthony De Soyza, PhD, Anshul Mangala, MD, Palak Shah, MD, Nishant Kumar Chauhan, MD, Nikita Jajodia, MPTH, Ashutosh Singhal, MD, Sakshi Batra, MD, Prof Ashfaq Hasan, MD, Sneha Limaye, MBBS, Sundeep Salvi, MD, Stefano Aliberti, MD, Prof James D Chalmers, PhD  The Lancet Global Health  Volume 7, Issue 9, Pages e1269-e1279 (September 2019) DOI: /S X(19) Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

2 Figure 1 Location of participating sites in the Indian bronchiectasis registry The Lancet Global Health 2019 7, e1269-e1279DOI: ( /S X(19) ) Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

3 Figure 2 Underlying causes of bronchiectasis in the Indian bronchiectasis registry The Lancet Global Health 2019 7, e1269-e1279DOI: ( /S X(19) ) Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

4 Figure 3 Extent and severity of bronchiectasis in the Indian bronchiectasis registry (A) Radiological distribution of bronchiectasis. Percentages refer to the lobes affected with the lingula treated as a separate lobe. Percentages add up to more than 100% as patients can have multiple lobes affected. (B) Dominant radiological pattern on CT. (C) Spirometry pattern at baseline. Low FVC was defined as spirometric restriction; obstruction was defined by FEV1/FVC <0·7 and normal spirometry required an FEV1 and FVC above 80% of predicted value. (D) Number of exacerbations treated with oral antibiotics. (E) Number of exacerbations requiring admission to a hospital. (F) Distribution of the multidimensional Bronchiectasis Severity Index. FEV1 /FVC=ratio of forced expiratory volume in 1 s/forced vital capacity. The Lancet Global Health 2019 7, e1269-e1279DOI: ( /S X(19) ) Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

5 Figure 4 Most commonly prescribed treatments for bronchiectasis and the quality-of-care indicators in the Indian bronchiectasis registry (A) Bronchodilators and inhaled treatments. (B) Airway clearance and mucoactive drugs. (C) Long-term antibiotic therapy. (D) Quality standards for bronchiectasis management in India. The numbers indicate the number of patients eligible. ICS=inhaled corticosteroids. LABA=long-acting β agonist. LAMA=long-acting muscarinic antagonist. LTRA=leukotriene receptor antagonist. *Includes ICS in combination with LABA, ICS monotherapy, and ICS, LABA, and LAMA in a single inhaler. The Lancet Global Health 2019 7, e1269-e1279DOI: ( /S X(19) ) Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions


Download ppt "Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network."

Similar presentations


Ads by Google